Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer

Abstract Clinical benefit of ALK tyrosine kinase inhibitors (ALK‐TKIs) in ALK‐rearranged lung cancer has been limited by the inevitable development of acquired resistance, and bypass‐molecular resistance mechanisms remain poorly understood. We investigated a novel therapeutic target through screenin...

Descripció completa

Dades bibliogràfiques

Autors principals:	Mi Ran Yun, Hun Mi Choi, You Won Lee, Hyeong Seok Joo, Chae Won Park, Jae Woo Choi, Dong Hwi Kim, Han Na Kang, Kyoung‐Ho Pyo, Eun Joo Shin, Hyo Sup Shim, Ross A Soo, James Chih‐Hsin Yang, Sung Sook Lee, Hyun Chang, Min Hwan Kim, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho
Format:	Artigo
Idioma:	Inglês
Publicat:	Springer Nature 2019-10-01
Col·lecció:	EMBO Molecular Medicine
Matèries:	acquired resistance ALK non‐small cell lung cancer statin YAP
Accés en línia:	https://doi.org/10.15252/emmm.201910581
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!